 | Up a level |
Diem, L; Ovchinnikov, A; Friedli, C; Hammer, H; Kamber, N; Chan, A; Salmen, A; Findling, O; Hoepner, R (2024). Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: real-world experience of two Swiss Multiple Sclerosis centers. Multiple Sclerosis and Related Disorders, 86 Elsevier 10.1016/j.msard.2024.105570
Schwarzwald, A; Salmen, A; Léon Betancourt, A; Diem, L; Hammer, H; Radojewski, P; Rebsamen, M; Kamber, N; Chan, A; Hoepner, R; Friedli, C (2023). Anti-neurochondrin antibody as a biomarker in primary autoimmune cerebellar ataxia - a case report and review of the literature. European journal of neurology, 30(4), pp. 1135-1147. Wiley 10.1111/ene.15648
Diem, L; Evangelopoulos, M E; Karathanassis, D; Natsis, V; Kamber, N; Hammer, H; Friedli, C; Chan, A; Helbling, A; Penner, I K; Salmen, A; Walther, S; Stegmayer, K; Hoepner, R (2022). Hypogammaglobulinemia: A contributing factor to multiple sclerosis fatigue? Multiple Sclerosis and Related Disorders, 68, p. 104148. Elsevier 10.1016/j.msard.2022.104148
Hammer, H; Kamber, N; Pistor, M; Diem, L; Friedli, C; Chan, A; Hoepner, R; Salmen, A (2022). Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS). Multiple Sclerosis and Related Disorders, 65, p. 104015. Elsevier 10.1016/j.msard.2022.104015
Achtnichts, L; Chan, A; Czaplinski, A; Derfuss, T; Du Pasquier, R; Findling, O; Gobbi, C; Hoepner, R; Kamber, N; Kamm, C P; Kuhle, J; Lalive, P; Lutterotti, A; Martin, R; Müller, S; Papadopoulou, A; Pot, C; Salmen, A; Schippling, S and Zecca, C (2019). Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. Clinical and translational neuroscience, 3(1), 2514183X1882207. Sage Publications 10.1177/2514183X18822073
Hammer, H; Salmen, A; Kamber, N; Friedli, Chr; Diem, L; Hoepner, R; Chan, A (January 2022). Primäre ZNS-Vaskulitis. Rheuma Schweiz Fachzeitschrift, 2022(1), pp. 46-54.
